Hepatitis B: Managing Chronic Infection, Antivirals, and Vaccination

Imagine finding out that a virus has been quietly living in your body for years. For millions of people worldwide, this is the reality of Hepatitis B, a viral infection that attacks the liver and can cause both acute and chronic disease. While many recover fully, about one in three adults with chronic infection face serious health risks, including cirrhosis and liver cancer. The good news? We have powerful tools to manage it. Modern guidelines from 2024 and 2025 have shifted dramatically toward earlier treatment and broader access to life-saving medications.

If you or someone you love has been diagnosed with chronic Hepatitis B, the landscape of care looks very different today than it did five years ago. Doctors are no longer waiting for severe damage to occur before starting treatment. Instead, they focus on suppressing the virus early to protect your liver long-term. This guide breaks down what you need to know about current treatments, who qualifies for them, and how vaccination plays a role in prevention.

Understanding Chronic Hepatitis B

To understand treatment, we first need to define what "chronic" means in this context. Chronic Hepatitis B is defined as the presence of the hepatitis B surface antigen (HBsAg) in the blood for at least six months. This marker tells us the virus is still active. According to the World Health Organization (WHO), approximately 296 million people were living with chronic HBV infection globally as of recent estimates. Tragically, this leads to around 820,000 deaths annually, mostly due to complications like cirrhosis and hepatocellular carcinoma (liver cancer).

The virus was first identified in the 1960s by Dr. Baruch Blumberg, a discovery that earned him the Nobel Prize. Since then, our understanding has evolved. We now know that the virus hides inside liver cells in a form called cccDNA (covalently closed circular DNA). Current antivirals suppress the virus but do not eliminate this reservoir, which is why treatment is often long-term. However, keeping the virus suppressed drastically reduces the risk of liver failure and cancer.

Who Needs Treatment Now?

This is where things have changed significantly. In the past, doctors often used a "wait and see" approach if liver enzymes were normal. Today, major guidelines-including the WHO 2024 guidelines and the updated 2025 clinical recommendations-advocate for much earlier intervention.

The goal is simple: stop the virus from replicating to reduce inflammation and fibrosis (scarring). Here is how different guidelines define eligibility:

• WHO 2024 Guidelines: Recommend antiviral therapy for all adults with HBV DNA levels ≥2,000 IU/mL, regardless of ALT (liver enzyme) levels or fibrosis stage. This simplifies access, especially in resource-limited settings.
• SABA 2022 Algorithm: Suggests treatment for HBeAg-positive patients aged 30 or older with HBV DNA >2,000 IU/mL, even if ALT levels are normal.
• AASLD 2018 Guidance: Recommends treatment for HBeAg-positive patients with HBV DNA >20,000 IU/mL and elevated ALT, or anyone with significant fibrosis or cirrhosis.

For those with compensated cirrhosis, treatment is recommended for everyone, no matter their viral load or enzyme levels. If you have decompensated cirrhosis, immediate oral antiviral treatment is crucial, alongside evaluation for liver transplantation.

First-Line Antiviral Medications

When treatment is needed, doctors typically prescribe nucleos(t)ide analogues. These drugs block the virus’s ability to replicate. There are three primary options considered first-line therapies:

1. Tenofovir Disoproxil Fumarate (TDF): Highly effective with a high barrier to resistance. However, long-term use can sometimes affect kidney function or bone density.
2. Entecavir (ETV): Also highly effective and well-tolerated, though it requires caution in patients with prior lamivudine exposure due to potential resistance.
3. Tenofovir Alafenamide (TAF): Marketed as Vemlidy, this is the newer generation tenofovir. It delivers the drug more efficiently to liver cells, allowing for lower systemic doses.

TAF has become a preferred option for many patients, particularly those with concerns about kidney health or bone strength. Clinical trials show that switching from TDF to TAF improves renal markers like proteinuria and albuminuria within the first 24 weeks and helps maintain bone mineral density. Both TDF and TAF are endorsed by major bodies like the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD).

Special Populations and Co-Infections

Hepatitis B rarely travels alone. Many patients also live with HIV, Hepatitis C, or Hepatitis D (HDV). The 2025 guidelines emphasize specific protocols for these groups.

HIV-HBV Co-infection: All co-infected patients should start HIV treatment with HBV-active antivirals immediately upon diagnosis, regardless of CD4+ T cell count. Drugs like TDF or TAF treat both viruses simultaneously.

Hepatitis D (HDV): Experts strongly recommend reflex HDV testing for all HBsAg-positive individuals. HDV can accelerate liver damage significantly. If present, management becomes more complex and may involve pegylated interferon (PEG-IFN) in addition to standard antivirals.

Pregnancy: Preventing mother-to-child transmission is critical. The WHO 2024 guidelines recommend starting tenofovir at week 28 of pregnancy for women with high viral loads (HBV DNA ≥5.3 log10 IU/mL). Newborns must receive the Hepatitis B vaccine and Hepatitis B Immune Globulin (HBIG) within 12 hours of birth.

The Role of Vaccination

While there is no cure that eliminates the virus completely yet, there is a highly effective vaccine. The Hepatitis B vaccine prevents infection in over 95% of recipients when given as a series of shots. It is part of routine childhood immunization schedules in most countries.

For unvaccinated adults exposed to the virus-such as through needle sticks or sexual contact-post-exposure prophylaxis involves administering both the vaccine and HBIG as soon as possible, ideally within 24 hours. This combination is highly effective at preventing chronic infection after exposure.

Monitoring and Lifestyle Management

Living with chronic Hepatitis B requires regular monitoring. Most specialists recommend visits every six months. During these visits, doctors check:

• HBV DNA levels: To ensure the virus remains suppressed.
• ALT Levels: To monitor liver inflammation.
• Fibrosis Status: Using non-invasive tests like FibroScan or blood markers to assess scarring.
• Liver Cancer Screening: Ultrasound and AFP blood tests every six months for high-risk patients.

Lifestyle choices matter too. Avoid alcohol entirely, as it accelerates liver damage. Maintain a healthy weight to prevent fatty liver disease, which compounds stress on the liver. Discuss any new medications or supplements with your doctor, as some can be harmful to the liver.

Future Directions: The Quest for a Cure

Research is moving fast. Scientists are developing novel therapies targeting cccDNA, the hidden reservoir of the virus. As of 2024, at least 15 compounds are in various stages of clinical development. These include capsid inhibitors, RNA interference agents, and entry inhibitors. The hope is that combination therapies will allow for finite treatment durations rather than lifelong medication. Leading experts predict that functional cures could be available for 30-40% of patients by 2030.